Citius Pharmaceuticals is trading at $0.58, up 7.19%; the October 26 LYMPHIR update may be supporting sentiment, but no connection to the gain is confirmed. - The update reported fourth-quarter shipments rose 120% sequentially to 792 units. - It also said 54 institutions had ordered LYMPHIR, and management was more than halfway to its year-end formulary goal. - No separate company announcement dated October 29 or source tied the gain to a specific event. The broader market is weaker and does not explain the rise.